

Combination Therapy For CNS Lymphoma

Tech ID: 33640 / UC Case 2023-138-0

TECHNOLOGY DESCRIPTION

There are currently no effective therapies for CNS lymphoma. Although B-cell malignancies express CD19, few therapeutic modalities (including CAR-T cells and bispecific T-cell engager antibodies) have overcome severe CNS neurotoxicity. New research suggests that CD19 expression at BBB may mediate neurotoxicity. Our inventor has shown regression of highly refractory CNS lymphoma with tafasitamab and lenalidomide.

STAGE OF DEVELOPMENT

Phase 2 L-MIND trial in patients with refractory non-Hodgkin lymphoma.

RELATED MATERIALS

- ▶ [Tafasitamab at the blood-brain barrier](#) - 01/23/2023

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney

Gemma.Rooney@ucsf.edu

tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

Refractory CNS Lymphoma,
B Cell Malignancy, CD19,
Tasasitamab, Lenalidomide

CATEGORIZED AS

- ▶ **Medical**
 - ▶ Disease: Cancer
 - ▶ Therapeutics

RELATED CASES

2023-138-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,
San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2024, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)